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Pediatric growing teratoma syndrome of the ovary
A case report and review of the literature
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Abstract
Rationale:Growing teratoma syndrome is defined as an increase in tumor size during or after systemic chemotherapy for germ cell
tumors. These cases involve normal tumor maker levels and histological features of only mature teratoma. We report a rare case of an
ovarian immature teratoma in a Japanese child that was diagnosed as growing teratoma syndrome.
Patient concerns: A 12-year-old girl presented a painful abdominal mass. She underwent left salpingo-oophorectomy for grade
1 immature teratoma in the left ovary. She did not undergo additional chemotherapy or radiotherapy. Four months later, she
presented with grade 3 immature teratoma disseminated into the abdomen and pelvis. Chemotherapy resulted in the tumor maker
levels returning to their normal ranges, although the tumors had grown slightly.
Diagnosis: The specimens resected by laparotomy after the chemotherapy consisted of mature tissue predominantly, although
primitive neuroepithelium was observed in a small part of the specimen. The pathological diagnosis was grade 1 immature teratoma,
notwithstanding the clinical diagnosis was growing teratoma syndrome based on the clinical features and pathogenesis.
Interventions: Laparotomy was performed at 7 months after the first operation, with resection of various tumors as well as the
rectum, sigmoid colon, residual left fallopian duct, and a small part of the ileum and omentum. Some small tumors at the parietal
peritoneum were ablated, although many tiny tumors around the uterus were left untreated.
Outcomes: The patient has been free from recurrence for 5 years.
Lessons: Growing teratoma syndrome can develop in children, and their tumor size is comparable to that in adolescents and
adults. Furthermore, development of growing teratoma syndrome from a primary germ cell tumor is presumably faster in children than
in adolescents and adults. Complete resection of all growing teratoma tissue is recommended, although fertility-sparing surgery
should be considered when possible.
Abbreviations: AFP = alfa-fetoprotein, BEP = bleomycin, etoposide and cisplatin, Beta-HCG = beta-human chorionic
gonadotropin, CA125 = carbohydrate antigen 125, CT = computed tomography, GP = gliomatosis peritonei, GTS = growing
teratoma syndrome, ICE = ifosfamide, carboplatin, etoposide, NSGSTs = non-seminomatous germ cell tumors, PET-CT = positron
emission tomography-computed tomography.
Keywords: growing teratoma syndrome, immature teratoma, ovarian tumor, pediatric
1. Introduction
Growing teratoma syndrome (GTS) is defined as an increase in
tumor size during or after systemic chemotherapy for germ cell
tumors, with normal tumor markers and histological features of
only mature teratoma. Logothetis et al[1] first used this term in
1982, although DiSaia et al[2] previously described a similar
phenomenon as “chemotherapeutic retroconversion” in 1977.
Amsalem et al[3] subsequently concluded that GTS and chemo-
therapeutic retroconversionwere probably the samephenomenon.
Although GTS is well known in male patients with germ cell
tumors, ovarian GTS is less commonly reported. According to Li
et al,[4] who reviewed 101 cases reported in the English literature,
ovarian GTS typically occurs in adolescents and young adults
(median age at diagnosis of primary immature teratoma: 22
years), and only 8 cases (7.9%) were diagnosed in children. Thus,
we report a rare case of an ovarian immature teratoma that was
diagnosed as GTS in a 12-year-old Japanese girl, and review the
literature regarding ovarian GTS in children.
2. Case report
A 12-year-old girl was admitted to a local hospital with a painful
abdominalmass.Abdominal computed tomography (CT) revealed
a large cystic mass containing calcified tissues and fat in the pelvic
cavity. Serum tumor marker levels were normal (alfa-fetoprotein
[AFP]: 11.25ng/mL, beta-human chorionic gonadotropin [beta-
HCG]: <0.10mg/mL), although serum CA125 levels were not
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measured. Left salpingo-oophorectomywas performed based on a
suspicion of a teratoma in the left ovary. Interestingly, malignant
cellswere not observed in the ascites despite previous rupture of the
tumor. Gross total resection was achieved and the pathological
diagnosis was grade 1 immature teratoma. No additional
chemotherapy or radiotherapy was performed.
Four months after the operation, abdominal CT revealed
multiple multinodular tumors with a maximum diameter of 9.0
cm in the pelvis, which contained calcified and fatty tissue (Fig. 1),
although the lymph nodes were not enlarged. Open biopsy was
used to obtain a specimen for histological evaluation, which
supported a diagnosis of grade 3 immature teratoma with
substantial primitive neuroepithelium. The patient was admitted
to our hospital soon after the recurrence with lower abdominal
distention and tenderness, and the elastic hard tumor was
palpable. Serum tumor maker testing revealed that her CA125
level was elevated to 198.2U/mL, but with normal levels of AFP
(5.1ng/mL) and beta-HCG (<0.40mIU/mL), despite the tumor’s
immaturity. Treatment was started using 1 cycle of bleomycin,
etoposide, and cisplatin (BEP) chemotherapy, which normalized
the CA125 levels, but the tumor became slightly enlarged. The
treatment was then changed to 1 cycle of ifosfamide, carboplatin,
and etoposide (ICE) chemotherapy, although the tumor became
further enlarged. After the ICE chemotherapy, positron emission
tomography-computed tomography (PET-CT) revealed abnor-
mal accumulation in the lower abdomen and pelvis, which was
considered indicative of a recurrent lesion (Fig. 2).
Given the tumor growth, despite normalization of tumor
markers after 2 chemotherapy cycles, we suspected GTS, which
requires a pathological diagnosis and total resection even in
asymptomatic cases. Thus, at 7 months after the first operation,
we performed laparotomy (Fig. 3) and observed numerous
disseminated tumors at the parietal and visceral peritoneum in
Figure 1. Abdominal computed tomography findings from 4 months after the
first operation revealed multiple multinodular tumors containing calcified and
fatty tissues (A). Invasion or lymph node swelling were not detected. Small
amounts of ascites were observed around the liver and in the pelvic cavity (B).
Figure 2. Post-chemotherapy findings from abdominal computed tomogra-
phy (A) and positron emission tomography–computed tomography (B). The
tumor had grown (A), and abnormal accumulation was observed (B).
Figure 3. The surgery revealed numerous disseminated tumors in the great
omentum.
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the lower abdomen and pelvis. We resected the rectum and
sigmoid colon because several disseminated tumors were firmly
adherent to the ventral side of the rectum. We also resected the
residual left fallopian duct and small parts of the ileum and
omentum with the tumors. Some small tumors at the parietal
peritoneum were ablated, although many tiny tumors around
the uterus were not treated. The abdominal lymph nodes were
not enlarged and the cytology results for the ascites were
negative.
Pathological analysis of the resected specimens revealed that
most of the specimen consisted of mature tissue, although
primitive neuroepithelium was observed in a small part of the
specimen (Fig. 4). The pathological diagnosis was grade 1
immature teratoma, which did not fulfill the pathological
criteria for GTS (histological evidence of only mature
teratoma). However, the pathogenesis agreed with that of
GTS, and the use of additional chemotherapy could have
converted the tumor into a mature teratoma. Thus, we
considered the tumor to be GTS. The postoperative course
was uneventful, and the patient was discharged 1 month after
the operation with no additional chemotherapy or radiothera-
py. The residual disseminated tumors have not enlarged during
the 5-year follow-up.
3. Discussion
Ovarian immature teratoma is a relatively rare tumor that arises
in young women, whose prognosis has been dramatically
improved by BEP chemotherapy after fertility-preserving surgery.
However, in the advanced cases with peritoneal metastasis, the
prognosis remains poor even after appropriate treatment. In these
cases, the diagnosis of GTS relies on 3 criteria:
(1) germ cell tumor growth during or after systemic chemother-
apy,
(2) the normalization of previously elevated serum tumor
markers, and
(3) the absence of immature components, other than mature
teratoma, in the resected specimen.
In this context, ovarian teratoma of any grade can induce
peritoneal implantation of mature glial tissues, which are known
as gliomatosis peritonei (GP), andGTS is considered a type of GP,
as both GTS and GP are associated with benign peritoneal glial
implants regardless of the original tumor’s malignancy grade.[5]
Two different pathogenic mechanisms have been proposed for
GTS:
(1) chemotherapy induces the malignant differentiation of
immature teratoma into a mature component[2] or
(2) chemotherapy destroys only the immature malignant cells
and spares the mature benign teratomatous elements.[1]
In the present case, the tumor had ruptured before the first
operation, which might have been the cause of GTS development.
Chemotherapy or radiotherapy was not performed after the first
operation because there was no evidence of malignant ascites,
dissemination was not detected using PET-CT, and the immature
teratoma was histologically classified as grade 1. However, the
disseminated tumor had enlarged at 4 months after the first
surgery, and the histological classification was a grade 3
immature teratoma with an elevated CA125 level. Thus, the
teratoma recurred as a higher-grade immature teratoma, rather
than as GTS, which was induced by the BEP and ICE
chemotherapy that was performed after the recurrence. Interest-
ingly, the present case developed from a recurrent tumor, whereas
the reported cases have developed from a primary tumor. In our
case, the pathological diagnosis after the last surgery was grade 1
immature teratoma, and we suspect that further chemotherapy
might have led to teratoma maturation that would ultimately
have fulfilled the criteria for GTS. Therefore, we clinically
diagnosed the tumor as GTS. Another important difference is that
the only elevated tumor marker in the present case was CA125,
while almost all reported cases have involved pre-treatment
elevations of AFP and HCG, AFP and CA125, or only AFP.[4]
Thus, although the cause for this discrepancy is unclear, the
tumor marker profile from present case appears to be rare.
The incidence of GTS in non-seminomatous germ cell tumors
of the testis is 1.9% to 7.6%.[1,6] In contrast, the incidence of
ovarian GTS in ovarian immature teratomas is 12% to 19%,[7,8]
with the GTS originating from the right ovary in 57% of cases
and the left ovary in 43% of cases. The median primary tumor
size was reportedly 18.7cm (range: 6–45cm) and median
subsequent tumor size was 8.6cm (range: 1–25cm). During
the interval between the primary treatment and the diagnosis of
ovarian GTS, the median tumor growth was 0.94cm/month
(range: 0.3–4.3cm/month) and the median interval to diagnosis
was 26.6 months (range: 1–264 months).[4] While the GTS
Figure 4. Pathological findings revealed mature tissue in almost all parts of the
tumor (A), but a primitive neuroepithelium, represented by a slightly high cell
density, in a small part of the tumor (B).
Oyama et al. Medicine (2020) 99:38 www.md-journal.com
3
usually occurs at the primary site of the germ cell tumor, 13% of
GTS cases involve metastatic sites.[9]
Ovarian GTS typically occurs in adolescents and young adults,
with a median age of 22 years at the diagnosis of primary
immature teratoma and only 7.9% of GTS cases being diagnosed
during childhood.[4] We have identified 17 cases of ovarian GTS
in children in the English literature (Table 1).[10–18] The youngest
patient was 4 years old at the diagnosis of the primary germ cell
tumor. The primary tumor size was 9 to 30cm, which is
comparable to in adolescent and adult patients, and our case
involved the smallest reported primary tumor size (9cm). The
histology of the primary germ cell tumor was immature teratoma
Table 1
Ovarian growing teratoma syndrome in children: review of the literature.
Primary germ cell tumor
Case Author Year n
Age
(yr)
Initial
symptoms Histology Location Size (cm)
Elevated
tumor
makers Treatment CT regimen
Tumor makers
after primary
Treatment
1 Moskovic et al[10] 1991 1 12 N/A IT Right ovary N/A AFP S + CT N/A Negative
2 Inaoka et al[11] 2003 1 5 Abdominal
distension
IT grade 2 Right ovary,
peritonuem
Huge AFP, CA125,
NSE
S + CT +
S + CT
Combination Negative
3 Amsalem et al[3] 2004 1 12 Abdominal pain
and distension
IT grade 2 Left ovary,
omentum
30 AFP, CA125,
LDH
S + CT BEP 3 cycles Negative
4 Nimkin et al[12] 2004 1 12 Abdominal
distension
IT grade 3 Right ovary,
omentum,
peritoneum
252520 AFP, CA125 S + CT N/A Negative
5 Tangjitgamol
et al[13]
2006 1 5 Abdominal pain IT grade 3 N/A 11 AFP S + CT BEP 2 cycles,
VAC 2 cycles
Negative
6 Zagame et al[7] 2006 3 12 N/A Mixed GCT N/A N/A N/A S N/A N/A
7 11 N/A IT N/A N/A N/A S N/A N/A
8 9 N/A Mixed GCT N/A N/A N/A S N/A N/A
9 Hsieh et al[14] 2009 1 4.5 N/A IT grade 3 Left ovary,
omentum,
peritoneum
131514 AFP S + CT VIP 1 cycle,
EC 1 cycle
Negative
10 Al-Jumaily et al[15] 2012 1 12 Abdominal pain
and distension
Mixed GCT Right ovary Huge AFP, hCG S + CT BEP 6 cycles,
VAC 4 cycles
Negative
11- 13 Bentivegna et al[8] 2015 3 <12 N/A N/A N/A N/A N/A N/A N/A Negative
14 Daher et al[16] 2015 1 4 Vomiting and
abdominal pain
Mixed GCT
(IT grade 3)
Left ovary,
omentum
17127 AFP, hCG S + CT VIP Negative
15 Rentea et al[17] 2017 1 12 Abdominal mass IT grade 3 Right ovary,
peritoneum
Large AFP S + CT BEP 4 cycles Negative
16 Frazer et al[18] 2019 1 12 Abdominal pain
and distension
Mixed GCT
(IT grade 3)
Right ovary 30 AFP S + S + CT CEB 2 cycles N/A
17 Our case 1 12 Abdominal pain
and mass
IT grade 1→3 Left ovary 9 CA125 S + CT BEP 1 cycle,
ICE 1 cycle
Negative
Growing teratoma syndrome lesion
Case
Time to
development Location Size (cm) Treatment
Residual
tumor Follow-up
Fertility-
preserving
surgery
1 During CT Pelvis N/A Resection Yes N/A N/A
2 6 mo after CT Around the liver and inferior
vena cava
N/A Resection Yes Mass remained
stable for 3 yr.
N/A
3 7 mo after Dx Right subdiaphragmatic area,
Pouch of Douglas
2–3 Resection, omentectomy, paraortic
lymph node dissection
No No reccurence
for 2 yr.
N/A
4 12 mo after CT Right subdiaphragmatic area,
mesentery, bilateral
paracolic gutters, broad
ligament, cul-de-sac.
N/A Resection3 Yes 144 mo N/A
5 2–3 mo after Dx
(during CT)
Right subdiaphragmatic area,
pelvis, cul-de-sac
16 Resection2 Yes No reccurence for
2 yr.
N/A
6 15 mo after Dx Retroperitoneum N/A Resection No 180 mo. N/A
7 7 mo after Dx Peritoneum N/A Resection No 184 mo. N/A
8 6 mo after Dx Peritoneal carcinomatosis N/A Resection Yes 177 mo. N/A
9 During CT Peritoneum N/A Resection, interferon a-2b, gamma-
knife surgery
N/A No reccurence for
2 yr.
N/A
10 6 mo after Dx
(during CT)
Right suprarenal area N/A Resection No Complete response
after 32 mo.
N/A
11-13 N/A N/A N/A N/A N/A N/A N/A
14 4 mo after Dx
(during CT)
Right subdiaphragmatic area,
omentum, appendix, pelvis
N/A Resection3 Yes Healty. N/A
15 6 mo after Dx
(during CT)
Right subdiaphragmatic area,
pelvis, cardiophrenic area
7.97.78.7 Resection, omentectomy, paraaortic
lymph node dissection, CT
(temozolomide, tretinoin, and
sorafenib)
Yes No new tumor growth. N/A
16 2 mo after S Pelvis and liver 86 Resection, partial hepatectomy No No reccurence for
18 mo.
N/A
17 3 mo after
recurrence
(during CT)
Pelvis Up to 9.8 Resection, lymph node dissection Yes Stable for 5 yr. Yes
AFP = alpha-fetoprotein, BEP = bleomysin + etoposide + cisplatin, CA-125 = carbohydrate antigen 125, CEB = carboplatin, etoposide, and bleomycin, CT = chemotherapy, Dx = diagnosis, EC = epirubicin +
cyclophosphamide, GCT = germ cell tumor, hCG = human chorionic gonadotropin, IT= immature teratoma, N/A = not available, NSE= neuron-specific enolase, S= surgery, VAC= vincristine + actinomycin +
cisplatin, VIP = etoposide + ifosfamide + cisplatin.
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in 9 cases and mixed germ cell tumor in 5 cases. Eleven patients
received chemotherapy, and the GTS diagnosis was made during
the chemotherapy in 6 cases (including the present case), which
suggests that GTS development is faster in children than in
adolescents and adults. The GTS may cause obstruction or
compression of abdominal structures, including the urinary tract,
vascular structures, and gastrointestinal tract.[11] Another report
described mesenteric compression with bowel necrosis, renal
failure due to ureteral compression, bowel obstruction, and bile
duct obstruction.[9] Fortunately, most children (including our
patient) did not develop serious symptoms.
The imaging-based diagnosis of GTS is supported by a mass
with increasing size that contains fat, calcification, or cystic
changes.[19] Thus, similar to in ovarian cancer, PET-CT provides
more information than CT alone, although a positive PET-CT
finding does not always reflect malignancy.[20] For example,
positive PET-CT findings could be related to the high rate of
glucose metabolism in brain tissues for cases of GTS (as in the
present case).[21]
The GTS lesions are refractory to chemotherapy, which
makes surgery the only curative treatment.[19] Complete
resection of all GST tissue is recommended, as incomplete
resection can lead to progression or malignant transformation.
For example, Shigeta et al reviewed 55 cases of ovarian
GTS and reported that GTS recurred in 12.7% of cases (7/
55) and underwent malignant transformation in 5.4% of cases
(3/55),[22] which can result in sarcoma, adenocarcinoma, or a
primitive neuroectodermal tumor and carcinoid.[23] Thus, if the
residual teratoma components are caused by chemotherapeutic
retroconversion, it appears logical that they would retain a high
level of histopathological genetic aneuploidy and their malig-
nant potential.[24–26] Therefore, complete surgical resection is a
highly desirable treatment,[27] although recurrence or malignant
transformation have not been reported in children. Neverthe-
less, fertility-sparing surgery is recommended when possible
based on the findings of 2 studies. Li et al reviewed 101 patients
with ovarian GTS and found that 5 of these patients became
pregnant during the interval between the primary disease and
GTS, with 1 patient becoming pregnant after the diagnosis of
ovarian GTS. Bentivegna et al[8] have also reported that 5 of 38
patients with ovarian GTS became pregnant after the diagnosis
of ovarian GTS. Both studies mention that fertility-sparing
surgery is recommended “when possible,” although the criteria
for evaluating this possibility remain unclear. Further studies
are needed to address this issue, as none of the reports regarding
the children in Table 1 indicate whether they underwent
fertility-sparing surgery, subsequently became pregnant, and
relapsed.
The recurrence rate for ovarian GTS is up to 83% in cases with
partial resection but only 0% to 4% in cases with complete
resection.[4] Among the reported children, only 2 cases involved
complete resection (Table 1), and the median recurrence-free
interval (from the final treatment for GTS to recurrence) was 24
months. These findings strongly indicate that a prolonged follow-
up is needed in cases with GTS.[22] Furthermore, several cases
involved malignant transformation of GTS, which might be
misdiagnosed as mature teratoma because the low-grade
primitive neuroepithelium is only present in a small part of the
specimen (as in the present case). Moreover, in the present case,
we elected to leave many disseminated small immature tumors,
and did not perform chemotherapy or radiotherapy because of
the paucity of the primitive neuroepithelium, although close
follow-up is necessary given the possibility of malignant
transformation.
4. Conclusions
We encountered a rare case of an ovarian immature teratoma that
was diagnosed as GTS in a Japanese child. In similar cases, the
GTS can develop during early childhood and the tumor size is
comparable to that in adolescents and adults, although the
development of the GTS from the primary germ cell tumor is
presumably faster in children. Complete resection of all GST
tissue is recommended based on the possibility of malignant
transformation, although fertility-sparing surgery should be
considered when possible.
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